Prevention of thrombosis during pregnancy

Israel Medical Association Journal

Volumn 4, Issue 10, 2002, Pages 794-797

  Vilela, Verônica Silva ^a   De Jesús, Nilson Ramirez ^a   Levy, Roger Abramino ^a  

^a NONE   (Brazil)

Author keywords

Anticoagulation; Antiphospholipid syndrome; Pregnancy; Thrombophilia

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CARDIOLIPIN ANTIBODY; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PREDNISONE; WARFARIN;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; CENTRAL NERVOUS SYSTEM MALFORMATION; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EMBRYOPATHY; FETUS WASTAGE; HEART VALVE PROSTHESIS; HUMAN; INFECTION; NERVOUS SYSTEM MALFORMATION; OSTEOPENIA; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; BLOOD COAGULATION TESTS; BONE DISEASES, METABOLIC; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FEMALE; FETUS; FIBRINOLYTIC AGENTS; GESTATIONAL AGE; HEART VALVE PROSTHESIS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; PLATELET AGGREGATION INHIBITORS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RISK FACTORS; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOPHLEBITIS; THROMBOSIS; TIME FACTORS; WARFARIN;

EID: 0036792386     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11.
2. Kerber IJ, Warr OS, Richardson C. Pregnancy in a patient with a prosthetic mitral valve. JAMA 1968;203:223.
3. Oakley C, Doherty P. Pregnancy in patients after valve replacement. Br Heart J 1976;38:1140-8.
4. Oates JA, Wood JJ. Oral anticoagulant drugs. N Engl J Med 1991;26:1865-71.
5. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association. Circulation 1994;89:1469-80.
6. Becker MH, Genieser NB, Finegold M, Miranda D, Spackman T. Chondrodysplasia punctata: is maternal warfarin a factor? Am J Dis Child 1975;129:356-9.
7. Shaul WL, Hall JG. Multiple congenital anomalies associated with oral anticoagulants. Am J Obstet Gynecol 1977;127:191-8.
8. Iturbe-Alesio I, Fonseca MC, Mutchnik O. Risks of anticoagulant therapy in pregnant woman with artificial heart valves. N Engl J Med 1986;315:1390-3.
9. Hirsh J, Cade JF, Gallus AS. Fetal effects of coumadin administered during pregnancy. Blood 1970;36:623-7.
10. Sherman S. Warfarin and fetal abnormalities. Lancet 1975;i:692-7.
11. Hall JAH, Paul RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980;68:122-40.
12. Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy [Review]. Chest 1992;102(4):385-90S.
13. Ginsberg JS, Greer I, Hirsch J. Use of antithrombotic agents during pregnancy [Review]. Chest 2001;119(1):122-31S.
14. Sarelli P, England MJ, Berk MR, et al. Maternal and fetal sequelae of anticoagulation during pregnancy in patients with mechanical heart valve prosthesis. Am J Cardiol 1989;63:1462-5.
15. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant woman with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000;160:191-6.
16. Lee PK, Wang RYC, Chow JSF, Cheung KL, Wong VCW, Chan TK. Combined use of warfarin and adjusted subcutaneous heparin during pregnancy in patients with an artificial heart valve. J Am Coll Cardiol 1986;8:221-4.
17. Ginsberg JS, Kowalchuk G, Hirsh J, Brill Edwards P, Burrows R. Heparin therapy during pregnancy: risks to the fetus and mother. Arch Intern Med 1989;149:2233-6.
18. Dahlman T, Lindval N, Hellgren M. Osteopenia in pregnancy during long-term heparin treatment: a radiological study post-partum. Br J Obstet 1990;97:221-8.
19. Barbour LA, Kirk SD, Steiner JF. A prospective study of heparin induced osteoporosis using bone densitometry. Am J Obstet Gynecol 1994;170:862-9.
20. Douketis JD, Ginsberg JS, Burrows RD. The effects of long-term heparin therapy on bone density: a prospective matched cohort study. Thromb Hemost 1996;75:254-7.
21. Hull R, Delmore T, Carter C. Adjusted Heparin versus warfarin sodium in the long term treatment of venous thrombosis. N Engl J Med 1982;306:189-93.
22. Gillis S, Shushan A, Eldor A. Use of low molecular weight heparin for prophylaxis and treatment of thromboembolism in pregnancy. Int J Obstet Gynecol 1992;39:297-301.
23. Nelson-Piercy C. Low molecular weight heparin for obstetric thromboprophylaxis. Br J Obstet Gynaecol 1994;101:6-8.
24. Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000;83:693-7.
25. Salazar E, Zajarias A, Gutierrez N, Iturbe I. The problem of cardiac valve prosthesis, anticoagulants and pregnancy. Circulation 1984;70:169-77.
26. Elkayam U. Anticoagulation in pregnant woman with prosthetic heart valves: a double jeopardy. J Am Coll Cardiol 1996;27:1704-6.
27. Oakley CM. Pregnancy and prosthetic heart valves [Review]. Lancet 1994;344:1643-4.
28. Hannia G, Thomas D, Michel PL. Pregnancy and prosthetic heart valves: a French Cooperative Study of 155 cases. Eur J Heart 1994;15:1651-8.
29. Douketis JD, Kearon C, Bates S. Risk of fatal embolism in patients with venous thromboembolism. JAMA 1998;279:458-62.
30. Prandoni P, Lensing AWA, Buller HR, et al. Comparison of subcutaneous low molecular weight heparin with standard heparin in proximal deep venous thrombosis. Lancet 1992;339:441-5.
31. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995;15:993-7.
32. Rai R, Cohen H, Dave M, Regan L. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997;314:253-7.
33. Kutteh WH. Antiphospholipid antibody associated recurrent pregnancy loss: treatment with heparin and low dose aspirin is superior to low dose aspirin alone. Am J Obstet Gynecol 1996;174:1584-9.
34. Lockshin MD, Druzin M, Qamar T. Prednisone does not prevent recurrent fetal death in woman with antiphospholipid antibody. Am J Obstet Gynecol 1989;107:439-43.
35. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992;166(5):318-23.
36. Inbar O, Blank M, Faden D, Tincani A, Lorber M, Shoenfeld Y. Prevention of fetal loss in experimental antiphospholipid syndrome by low-molecular-weight heparin. Am J Obstet Gynecol 1993;169(2 Pt 1):423-6.
37. Cowchock S. Treatment of antiphospholipid syndrome in pregnancy [Review]. Lupus 1998;7:S95-7.
38. Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996;14:131-6.
39. Jesús NR, Vilela VS, Albuquerque EMN, Trajano A, Levy RA. Efficacy and safety of the treatment of antiphospholipid syndrome during pregnancy with coumadin from week 14 to 36 [Abstract]. Arthritis Rheum 2001;44:s563.